To determine the plasma epinephrine thresholds for its metabolic and hemodynamic actions and plasma epinephrine metabolic clearance rates, 60-min intravenous epinephrine infusions at nominal rates of 0.1, 0.5, 1.0, 2.5, and 5.0 microgram/min were performed in each of six normal human subjects. These 30 infusions resulted in steady-state plasma epinephrine concentrations ranging from 24 to 1,020 pg/ml. Plasma epinephrine thresholds were 50-100 pg/ml for increments in heart rate, 75-125 pg/ml for increments in blood glycerol and systolic blood pressure, 150-200 pg/ml for increments in plasma glucose (the resultant of increments in glucose production and decrements in glucose clearance), blood lactate, blood beta-hydroxybutyrate, and diastolic blood pressure, and greater than 400 pg/ml for early decrements in plasma insulin. Changes in blood alanine, plasma glucagon, plasma growth hormone, and plasma cortisol were not detected. At steady-state plasma epinephrine concentrations of 24-74 pg/ml, values overlapping the basal normal range, the mean (+/-SE) plasma metabolic clearance rate of epinephrine was 52 +/-4 ml x min-1 x kg-1; this value rose to 89 +/-6 ml x min-1 x kg-1 (P less than 0.01) at steady-state epinephrine concentrations of 90-1,020 pg/ml. We conclude that in human subjects: (a) the plasma epinephrine thresholds for its hemodynamic and metabolic actions lie within the physiologic range, (b) epinephrine and norepinephrine accelerate their own metabolic clearance, and (c) […] A B S T R A C T To determine the plasma epinephrine thresholds for its metabolic and hemodynamic actions and plasma epinephrine metabolic clearance rates, 60-min intravenous epinephrine infusions at nominal rates of0.1, 0.5, 1.0, 2.5, and 5.0,ug/min were performed in each of six normal human subjects. These 30 infusions resulted in steady-state plasma epinephrine concentrations ranging from 24 to 1,020 pg/ml. Plasma epinephrine thresholds were 50-100 pg/ml for increments in heart rate, 75-125 pg/ml for increments in blood glycerol and systolic blood pressure, 150-200 pglml for increments in plasma glucose (the resultant of increments in glucose production and decrements in glucose clearance), blood lactate, blood f3-hydroxybutyrate, and diastolic blood pressure, and >400 pg/ml for early decrements in plasma insulin. Changes in blood alanine, plasma glucagon, plasma growth hormone, and plasma cortisol were not detected. At steadystate plasma epinephrine concentrations of 24-74 pg/ml, values overlapping the basal normal range, the mean (±SE) plasma metabolic clearance rate of epinephrine was 52±4 ml min-l kg-l; this value rose to 89±6 ml * min-' kg-' (P < 0.01) at steady-state epinephrine concentrations of 90-1,020 pg/ml. We conclude that in human subjects: (a) the plasma epinephrine thresholds for its hemodynamic and metabolic actions lie within the physiologic range, (b) epinephrine and norepinephrine accelerate their own metabolic clearance, and (c) epinephrine is 10 times more potent than norepinephrine.
INTRODUCTION
Sensitive isotope derivative methods (1) have made it possible to measure the plasma concentrations of norepinephrine and epinephrine in the basal state and in diverse physiologic and pathophysiologic states in Received for publication 30 Jatuary 1980. 94 humans (2) . Although the multiple metabolic and hemodynamic actions of the catecholamines are well known (3, 4) , the plasma catecholamine concentrations required to produce these effects have not been fully defined. The finding that, in order to produce measurable effects, plasma norepinephrine concentrations must be raised to levels considerably higher than those occurring under most physiologic conditions (5) indicates that the biologic actions of norepinephrine are primarily attributable to its sympathetic postganglionic neurotransmitter function. In some physiologic states, such as vigorous exercise, and in a variety of pathophysiologic states, plasma norepinephrine concentrations are high enough to produce biologic actions. Thus, norepinephrine may also subserve a hormonal function under these conditions (5) .
The plasma concentrations of the adrenomedullary hormone epinephrine required to produce its biologic actions have not been established. Clearly, this information is critical to rational interpretation of measurements of plasma epinephrine levels. To determine these threshold levels, we have infused epinephrine at five nominal rates into each of six normal human subjects to produce steady-state plasma epinephrine concentrations that span the physiologic range. These studies demonstrate that the threshold plasma epinephrine concentrations lie within the physiologic range.
METHODS
Six normal subjects (five men and one woman), whose characteristics are listed in Table I , each consented to five 60-min epinephrine infusions at nominal rates of 0.1, 0.5, 1.0, 2.5, and 5.0 Ag/min. All infusions were performed after an overnight fast, including abstinence from caffeine and tobacco; subjects were supine throughout each infusion. In a given subject, infusions were separated by intervals of at least 1 (8) , glucagon (9) , and growth hormone (10) were determined by radioimmunoassay; cortisol was measured with a competitive protein binding technique (11) . Microfluorometric enzymatic techniques were used to measure blood levels of lactate (12) , alanine (13), ,8-hydroxybutyrate (14) , and glycerol (15) . Glucose kinetics were determined by means of a primed, continuous infusion of [6,6-2H2] glucose (16, 17) . Isotopic enrichment of plasma glucose was determined in the 6-0-acetyl-1,2:3,5 di-0-(n-butaneboronyl)a-D-glucofuranose derivative by combined gas chromatography and mass spectrometry with selected ion monitoring. Tracer infusion was begun 90 min before the infusion of epinephrine with a priming dose calculated to produce 1.75% enrichment of the extracellular glucose pool, followed by continuous infusion of tracer at 1.75% of the estimated basal glucose turnover rate. Isotopic enrichment of plasma glucose reached a plateau before each epinephrine infusion. Glucose turnover rates in the basal state (before epinephrine infusion) were calculated using the standard isotope dilution equation (18) . Rates of glucose production and glucose utilization were estimated by means of Steele's equations for nonsteady-state conditions (19) as validated for the glucose system (20) . A value of 65% of the extracellular space was used as the mixing pool to correct for the lack of instantaneous mixing throughout the extracellular glucose pool (21) . The plasma glucose clearance rate-an index of the ability of tissues to remove glucose from plasma, independent of the prevailing plasma glucose concentration-was calculated by dividing the rate of glucose utilization by the concurrent plasma glucose concentration (22 (pMCRE) were calculated by dividing the measured epinephrine infusion rate by the difference between the p[E]ss and the basal preinfusion plasma epinephrine concentration (5) . Two points must be noted about this calculation. First, it requires the assumption that endogenous epinephrine released into the circulation at basal rates continues during the infusion of epinephrine. If endogenous release of epinephrine ceases during epinephrine infusion, this equation will overestimate the pMCRE, especially at the lower p[E]ss levels. Second, to the extent that the extremity is an organ of epinephrine uptake (and net norepinephrine [NE] release), as suggested by arteriovenous concentration differences (23) , this calculation will overestimate the pMCRE (and underestimate the pMCRNE). From the data of our earlier study, using this method to calculate the pMCRNE (5), we calculate a value for the basal rate of metabolic clearance of norepinephrine (2.1 liter/min), which agrees with that found by Essler et al. (24) 
RESULTS
Mean (±SE) plasma epinephrine and norepinephrine concentrations at each of the five nominal epinephrine infusion rates are illustrated in Fig. 1 . Achieved within 10 min, the mean (±SD) p[E]ss values were 5430, 114+28, 219t83, 412t89, and 715+228 pg/ml at nominal epinephrine infusion rates of 0.1, 0.5, 1.0, 2.5, and 5.0 ,tglmin, respectively. The measured epinephrine infusion rates, determined from the infusate epinephrine concentrations, are given in Fig. 1 (25) , glucose production rose transiently, returning to near base line by 60 min, glucose utilization did not change, and glucose clearance declined and remained suppressed during the infusion of epinephrine at the higher infusion rates (Fig. 3) . The plasma insulin response to the larger doses of epinephrine was biphasic with an initial decline followed by a gradual rise and, after termination of the epinephrine infusions, a sharp rise (Fig. 4) .
The data used to estimate the plasma epinephrine thresholds for its hemodynamic and metabolic actions are illustrated in Figs. 5-8 , where the p[E]ss for each infusion is plotted against the change in each measured variable during that infusion. Except where indicated, changes in these variables represent the difference between the basal value and the value after 60 min of epinephrine infusion.
The plasma epinephrine threshold for increments in heart rate was 50-100 pg/ml, for increments in systolic blood pressure the threshold was 75-125 pg/ml, whereas for decrements in diastolic blood pressure, the threshold was 150-200 pg/ml (Fig. 5) . Increments in the plasma glucose concentration and glucose production and decrements in glucose clearance occurred at threshold values of 150-200 pg/ml (Fig. 6) glycerol, 75-125 pg/ml (Fig. 7) . The threshold for the initial suppression of plasma insulin was 400 pg/ml, higher than that of the other responsive variables ( 8). These plasma epinephrine thresholds are summarized in Table III .
DISCUSSION
From mean (±SD) basal values of 34±18 in 60 normal subjects studied in our laboratory, mean plasma epinephrine concentrations rise nearly 2-fold during quiet standing (6), -3-fold during cigarette smoking (26), from 2-13-fold during mild to heavy exercise (27) , and 50-fold during insulin-induced hypoglycemia (28) . Notably, physiologic decrements in the plasma glucose concentration-from 95 to 60 mg/dl-were associated with a nearly seven-fold rise in plasma epinephrine levels, with a maximum mean value of 230 pg/ml (29) . Similar values are achieved during elective cholecystectomy,2 and higher values occur in various pathophysiologic states such as diabetic ketoacidosis (30), acute myocardial infarction (31) , and pheochromocytoma (32) . Clearly, interpretation of the biologic significance of these plasma epinephrine measurements requires knowledge of the plasma epinephrine concentrations necessary to produce measurable biologic actions.
In the present studies, infusions of graded doses of epinephrine into normal human subjects generally pro-duced the effects anticipated (3, 4) . These included increments in heart rate, widening of the pulse pressure, increments in plasma glucose (the resultant of a transient increase in glucose production and a sus- tained decrease in glucose clearance), blood lactate, blood glycerol, and blood f3-hydroxybutyrate, and initial decrements in plasma insulin. One discrepancy with earlier studies (25, 33, 34) mlmin-1 kg-l; at higher p[NE]ss the pMCRNE was 39+3 ml min-l'kg-l (P <0.02). These findings are complementary to the recent observation that the * * clearances of epinephrine and norepinephrine are 500 --1-~'-sharply reduced during,8-adrenergic blockade (but tinaltered during a-adrenergic blockade) in humans (35) . Thus, the catecholamines appear to regtulate their own metabolic clearance through /8-adrenergic mechanisms, a potentially important level of modutlation of > -----ej--the biologic expression of sympathoadrenal activity.
We conclude that in human subjects: (a) the plasma 500 1000 epinephrine thresholds for its hemodynamic and metabolic actions lie within the physiologic range, (b) epinephrine and norepinephrine accelerate their own --.-----imetabolic clearance, and (c) epinephrine is -10 times i* . . more potent than norepinephrine. ance by -70%. Analysis of the primary data from an earlier study (5) from our laboratory revealed a similar effect of norepinephrine on its metabolic clearance.
At p[NE]ss of 229-345 pg/ml, the pMCRNE was 25±4 
